• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation

    11/26/24 8:35:00 AM ET
    $APVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APVO alert in real time by email

    Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform" at Cambridge Healthcare Institute's, Pep Talk 2025

    SEATTLE, WASHINGTON / ACCESSWIRE / November 26, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, todayannounced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform," at the Cambridge Healthcare Institute's, Pep Talk conference, in January 2025.

    The presentation will illustrate how Aptevo leverages its proprietary platforms to rapidly advance the development of innovative cancer therapies and use clinical candidates Mipletamig and ALG.APV-527 to exemplify proof of concept for its modular biotherapeutic approach, reducing risk and increasing the likelihood of clinical success for future drug candidates. Aptevo has five compounds in clinical and preclinical development and anticipates introducing a new molecule in early 2025.

    This leadership opportunity underscores Aptevo's technology and its commitment to driving innovation in functional drug production, creating molecules that perform in the clinic the way they were designed to perform at inception.

    "Therapeutic candidates are often talked about once they are in human trials, especially when positive results are generated. But the genesis of those drugs and the speed with which they are produced, serves as the backbone of all therapeutic innovation. We work to create molecules that will be safe and tolerable in humans and target cancers as directly and effectively as possible," said Dr. Pavlik. "My presentation will describe how employing modular biotherapeutics can drive pipeline productivity, a critical capability, especially for smaller biotechnology companies navigating a competitive landscape. More specifically, we will explore the power of Aptevo's ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, which enable the rapid development of novel multispecific biotherapeutics, accelerating the journey from drug discovery to clinical trials and ultimately patient benefit."

    About Dr. Pavlik

    Peter Pavlik, PhD, serves as the Senior Director of Protein Engineering at Aptevo Therapeutics. In his career at Aptevo and previously MedImmune/AstraZeneca and Los Alamos National Labs, he has implemented novel technologies to streamline discovery of binding domains and their incorporation into stable and efficacious biotherapeutics. Dr. Pavlik has oversight over all processes currently used at Aptevo which are optimized to multiple areas of drug development from target validation to antibody discovery to IND and to clinic. Peter has a unique understanding of the biopharma industry from the large and small company perspectives.

    About Aptevo Therapeutics

    Aptevo Therapeutics Inc. (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard of care venetoclax + azacitidine. Mipletamig has orphan status for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR® and ADAPTIR-FLEX®. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit www.aptevotherapeutics.com.

    Safe Harbor Statement

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations regarding the effectiveness of its ADAPTIR® and ADAPTIR-FLEX® platform technologies and whether such technologies will accelerate drug discovery and development, statements related to the performance of Aptevo's drug candidates in the clinic and whether such performance will translate into improved patient outcomes, statements related to the progress of and enthusiasm for Aptevo's preclinical and clinical programs, statement related to Aptevo's expectation to add another targeted preclinical asset to the pipeline, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "believes," "expects," "potential," "designed," "engineered," "innovative," "initiate," "allow," "promise," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.

    There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients in clinical trials, uncertainties inherent in the results of preliminary or interim data and preclinical and clinical studies being predictive of the results of later-stage clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine as well as the war between Israel and Hamas, and macroeconomic conditions such as rising inflation and interests rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.

    Aptevo Therapeutics
    Miriam Weber Miller
    Email: [email protected] or [email protected]
    Phone: 206-859-6629

    SOURCE: Aptevo Therapeutics



    View the original press release on accesswire.com

    Get the next $APVO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • What session will Peter Pavlik, PhD, chair at the Pep Talk conference?

      Peter Pavlik, PhD, will chair a session on "Bi and Multispecific Biologics" and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR™ Platform".

    • What will Aptevo's presentation at the Pep Talk conference illustrate?

      Aptevo's presentation will demonstrate their R&D capabilities and the potential of their ADAPTIR™ and ADAPTIR-FLEX™ platforms in advancing innovative cancer therapies, illustrated through their drug candidates Mipletamig and ALG.APV-527.

    • What is the mission of Aptevo Therapeutics?

      Aptevo aims to improve treatment outcomes and transform the lives of cancer patients through the development of novel bispecific immunotherapies.

    • When is Aptevo expected to introduce a new molecule?

      The anticipated new molecule from Aptevo is expected to be introduced in early 2025, adding to their pipeline of ongoing clinical and preclinical candidates.

    • What are some potential risks stated in Aptevo's forward-looking statements?

      Risks include adverse clinical developments, outcomes differing from expected results, changes in regulatory environments, and challenges in securing funding and partnerships.

    Recent Analyst Ratings for
    $APVO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $APVO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Aptevo Therapeutics Inc.

      SCHEDULE 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      7/8/25 2:11:55 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aptevo Therapeutics Inc.

      DEF 14A - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/7/25 12:11:40 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Aptevo Therapeutics Inc. (0001671584) (Filer)

      7/1/25 5:05:48 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Aptevo Therapeutics with a new price target

      Roth Capital reiterated coverage of Aptevo Therapeutics with a rating of Buy and set a new price target of $50.00 from $64.00 previously

      5/28/21 8:33:45 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Huebner Dirk claimed no ownership of stock in the company (SEC Form 3)

      3 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      7/9/25 5:32:20 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, GC, BD & Corp Affairs Kwon Soyoung converted options into 4 shares, increasing direct ownership by 19% to 25 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:36:04 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, COO Lamothe Jeffrey G. converted options into 5 shares, increasing direct ownership by 16% to 36 units (SEC Form 4)

      4 - Aptevo Therapeutics Inc. (0001671584) (Issuer)

      3/4/25 4:35:19 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

      Also giving an in-session talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," showcasing Aptevo's drug engineering and rational drug design expertise SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO) today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled "Bi and Multispecific Biologics" and present a talk,"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR® Platform," at the Cambridge Healthcare Institute's Pep Talk conference today.DetailsSession Title: Bi and Multispecific BiologicsTalk Title: Modular Multispecific

      1/15/25 8:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

      SEATTLE, WASHINGTON / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common s

      12/12/24 12:50:00 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

      Two of three patients achieved both complete remission and MRD-negative statusHigh response rates observed in earlier studies continue in ongoing mipletamig trialCohort 2 enrollment commencing SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel bispecific immune-oncology therapeutics based on its proprietary ADAPTIR® and ADAPTIR-FLEX® platform technologies, today announced 100% of patients achieved remission* within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia (AML) Phase 1b trial, including two patients who experienced complete remission with minimal residual d

      12/12/24 9:00:00 AM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $APVO
    Leadership Updates

    Live Leadership Updates

    See more
    • BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors

      NEW YORK and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSXV:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. Dr. Jane Gross is a highly experienced biotech executive with over 30 years in leading research and development teams from discovery through preclinical evaluation and clinical development of therapeutics for the treatment of cancer and autoimmune and inflammatory diseases. Dr. Gross currently serves as an Independ

      11/2/21 9:00:00 AM ET
      $AMGN
      $APVO
      $BCTX
      $BMY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $APVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aptevo Therapeutics Inc.

      SC 13G/A - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/14/24 3:45:38 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      11/8/24 2:57:35 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aptevo Therapeutics Inc.

      SC 13G - Aptevo Therapeutics Inc. (0001671584) (Subject)

      2/14/24 3:24:02 PM ET
      $APVO
      Biotechnology: Pharmaceutical Preparations
      Health Care